IRB approval is not FDA approval. The cellular products studied are investigational and are not approved by the FDA. Nov. 30, 2021
“Retrospective Case Series Study of Dendritic Cell-Cytokine Induced Killer Cell Therapy in Previously Treated Subjects with Lymphatic Leukemia and Peritoneal Cancer”
Protocol #: BHI21-RCS-DCCIK
Institute of Regenerative and Cellular Medicine IRB Approval #: IRCM-2-21-308